SLE-DAS responder index: a novel outcome measure with high performance for physician and patient outcomes in anifrolumab phase 2–3 trials
- 6 April 2026
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Abstract
Objectives: The objectives of this study were to develop and evaluate the performance of the novel SLE-DAS Responder Index (RI) as an efficacy end point in SLE trials, and to assess the utility of SLE-DAS in identifying moderate-to-severe disease activity (MSDA). Methods: This post-hoc analysis pooled data from the placebo arms of three randomized controlled trials of anifrolumab (MUSE, TULIP-1, and TULIP-2). The SLE-DAS RI was defined as a reduction in SLE-DAS of ≥1.72 and a score of ≤7.64 at week 52. Associations between SLE-DAS RI and changes in disease activity, glucocorticoid exposure, and health-related quality of life (HR-QoL) were evaluated using regression models. The predictive performance of SLE-DAS RI for HR-QoL was compared with the BILAG-based Composite Lupus Assessment (BICLA) and the SLE Responder Index (SRI-4). Flare occurrence was analysed using the SLE-DAS flare tool and Cox regression. The ability of SLE-DAS to identify MSDA was assessed at screening and week 12, using BILAG-2004 and SLEDAI-2K as comparators. Results: Of 438 patients, 34.0% achieved SLE-DAS RI response at week 52. Responders showed greater reductions in disease activity, lower cumulative glucocorticoid exposure, and significantly improved HR-QoL. Multiple linear regression identified SLE-DAS RI response as the most significant predictor of HR-QoL improvements across multiple domains. SLE-DAS RI responders had 41.9% lower risk of flare. At screening, SLE-DAS MSDA identified 96.1% of patients with MSDA and better reflected HR-QoL burden at week 12. Conclusion: The SLE-DAS RI is a robust efficacy end point in SLE trials, associated with sustained disease control and meaningful improvements in patient-reported outcomes. SLE-DAS also enables accurate identification of MSDA, supporting its broader utility in trial design.Keywords
This publication has 40 references indexed in Scilit:
- OMERACT systemic lupus erythematosus domain surveySeminars in Arthritis and Rheumatism, 2024
- Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health‐Related Quality of LifeArthritis Care & Research, 2024
- What is the best instrument to measure disease activity in SLE? – SLE-DAS vs Easy BILAGAutoimmunity Reviews, 2023
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled TrialArthritis & Rheumatology, 2022
- Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems TallyArthritis Care & Research, 2021
- Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus ErythematosusArthritis & Rheumatology, 2017
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- Development and validation of a disease‐specific health‐related quality of life measure, the LupusQol, for adults with systemic lupus erythematosusArthritis Care & Research, 2007
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990